FDA Grants Approval to Darmiyan’s BrainSee AI for Early Alzheimer’s Detection

In a groundbreaking move, the Food and Drug Administration (FDA) has granted Do Novo approval to the BrainSee medical AI software developed by Darmiyan. This innovative software is designed to predict the likelihood of a patient developing Alzheimer’s disease within five years, providing doctors with a valuable tool for early intervention. Revolutionizing Alzheimer’s detection Darmiyan’s